The IMF once again downgraded its outlook for global growth, hurt by a slowdown in emerging markets.
Pharmaceutical companies’ U.S. revenue growth for leading drugs has far outpaced demand, thanks to the industry’s pricing power, a Wall Street Journal analysis shows.
China’s stock market has burned more than 40% of its value since June as investors fret over the health of the world second largest economy. But one prominent London hedge fund says now is the time to buy.
SABMiller reported a fall in second-quarter revenue because of weaker emerging-market currencies, ahead of next week’s deadline for Anheuser-Busch InBev to make a bid for the brewer or walk away.
DuPont said its chairman and chief executive, Ellen Kullman, would retire as the company slashed its outlook and said it would speed up cost-cutting plans.
The U.S. trade gap expanded in August as a strong dollar, weak commodity prices and slow overseas growth weighed on demand for American-made goods.
Nelson Peltz’s $2.5 billion bet on General Electric came without a typical activist investor’s arsenal of attack-like demands for board seats or calls to split up the company
U.S. industries as diverse as aerospace, agriculture and apparel laud the historic Trans-Pacific Partnership struck Monday. Others cite shortcomings.
The U.S. Treasury sold a new government security maturing in three months at a yield of zero for the first time on record amid the highest demand since June.
Chinese sportswear makers Anta and Xtep are looking up, thanks to newfound consumer demand and previous changes in supply.